A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
Clinical trial NCT06465446 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06465446
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-01
- Primary completion
- 2026-06-01
- Enrollment
- 202
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.